[ad_1]
IIn an unexpected development, Mallinckrodt (MNK) filed a lawsuit accusing the federal government of illegally resetting a benchmark used to calculate Medicaid's rebates for its most important drug, a move that could cost it money. hundreds of millions of dollars. its future R & D efforts.
The issue is the amount the company owes the Centers for Medicare and Medicaid Services for its controversial Acthar Gel treatment, which is used primarily to treat childhood spasms and has been a glaring example of the high cost of drugs. In the last five years, the wholesale price has increased by 20% and a bottle now costs about $ 39,000, making it a costly proposition for public and private payers.
Unlock this item by subscribing to STAT Plus and enjoy your first 30 days for free!
TO START
What is it?
STAT Plus is a premium subscription offering scalable biopharmaceutical market coverage and in-depth scientific reports from a team with decades of experience in the industry.
What is included?
- Authoritative coverage and biopharmaceutical analysis, interviews with industry pioneers, policy analysis and early review of advanced labs and early stage research
- Subscriber Networking Events and Group Discussions Across the Country
- Monthly live subscriber discussions with our reporters and experts in the field
- Discounted tickets for industry events and early access to industry reports
[ad_2]
Source link